Lymph nodes are key control centers in the immune system and play an important role in defending the body against infections ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; ...

New methods of classifying patients could pave the way for more personalized treatment approaches, a new report states. The methods of subtyping diffuse large B-cell lymphoma (DLBCL) have changed over ...

In his closing thoughts, Dr Gordon discusses navigation of treatment resistance in DLBCL management. Leo Gordon, MD: People who are febrile who have low white [blood cell] counts are at risk for ...

New DLBCL trials test bispecifics with chemo, BTK add-ons, and MRD-guided preemptive allo CAR-T to cut relapse risk. The ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. We are so lucky in DLBCL to make more rapid ...

Follow-up data from the EPCORE NHL-1 trial lend further support to the efficacy and safety of single-agent epcoritamab (Epkinly) in the treatment of relapsed/refractory diffuse large B-cell lymphoma ...

Add Yahoo as a preferred source to see more of our stories on Google. The trial evaluated epcoritamab as a monotherapy against R-GemOx Danish biotechnology company Genmab has announced top line ...

At the recent American Society of Hematology (ASH) meeting, researchers presented early data from a phase II study evaluating mosunetuzumab (Lunsumio) as frontline monotherapy for elderly patients ...

Please provide your email address to receive an email when new articles are posted on . The addition of brentuximab vedotin to lenalidomide and rituximab improved survival for certain patients with ...

Mohamad Ali Najia, PhD, bioengineer and stem cell biologist, has been awarded a fellowship for early career scientists to research how the legacy of humans’ ancient battles with viruses may play a ...